PharmaResources was founded in 2007 as a one-stop integrated CRO/CDMO service provider for new drug development and commercial production, committed to drug discovery, pharmaceutical process research and development, and commercial production.
The company’s new drug development services cover the entire process of preclinical new drug research, mainly including drug discovery and process research and development services. In particular, drug discovery service helps customers design, screen and optimize hit compounds and lead compounds, coupled with structural improvement and preliminary safety screening, to obtain candidate compounds with intellectual property rights and excellent druggability. Process research and development service provides new drug process chemistry services and innovative synthetic process development for pharmaceutical companies around the world, helping customers to achieve cost-effective, safe, green and reliable commercial production of intermediates and APIs in scales from kilograms to tons. Relying on its own advantages in pharmaceutical technology, the company is also engaged in customized production services of key intermediates for new drugs, as well as independent development and production of specialty API intermediates with complex chemical structures and high synthesis difficulties.
In March 2021, the company’s IPO application for GEM board was accepted by Shenzhen Stock Exchange, and in April 2022, it passed the examination of the Listing Committee. On July 8, 2022, the China Securities Regulatory Commission approved the application of PharmaResources (Shanghai) Co., Ltd. for initial public offering of shares and listing on Shenzhen GEM. On October 18, 2022, PharmaResources made an initial public offering of 19.25 million A shares and was listed on the GEM board.
As the company’s core value “science-focused with continuous innovation” advocates, “science and innovation” is always the target of the company and all members of PharmaResources, despite of any changes in the internal and external environment. Only by constantly pursuing excellence in science and technological innovation can we meet the ever-changing needs of our customers and the market, while ensuring the sustainable competitiveness of the company.
PharmaResources Marketing-CADD Service
Mar 14, 2023
Posted by PharmaResources